Semnur Pharmaceuticals, Inc. (SMNRW)
US Markets
$0.08
-12.22%
Closing price as of 2026-07-30 · Source: TEK2day Finance
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.
Quarterly Financials
| Metric | 2025-03-31 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -665K | -152.6M | -6.2M | -4.6M |
| Net Income | -665K | -152.6M | -6.2M | -4.6M |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.8M | -3.3M | -4.7M | -160.4M |
| Net Income | -3.8M | -3.3M | -4.7M | -160.4M |